Original Article
Copyright ©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 7, 2013; 19(9): 1387-1395
Published online Mar 7, 2013. doi: 10.3748/wjg.v19.i9.1387
Table 1 Basal demographic and biochemistry criteria of all patients (mean ± SD)
CriteriaTotal
Number102
Age (yr)32.5 ± 7.3
Sex (male/female)90/12
BMI25.6 ± 2.7
Baseline Hb (g/dL)14.07 ± 1.1
plt (× 103/μL)238.5 ± 62.7
WBCs (× 103/μL)6.3 ± 1.4
ALT > ULN, n (%)78 (76.5)
Creatinine level (mg/dL)0.91 ± 0.44
Baseline HCV RNA (log IU/mL)5.4 ± 0.7
Metavir fibrosis stage, n (%)
F169 (67.7)
F230 (29.4)
F33 (2.9)
Grade of inflammation, n (%)
A164 (62.7)
A233 (29.4)
A35 (5.4)
PEG IFN, n (%) (dose)
α2a72 (70.6) (180 μg/wk)
α2b30 (29.4) (1.5 μg/kg per week)
Ribavirin dose (mg/kg per day)12.5 (10-15)
HCV genotype (G), n (%)G4, 62 (60.8); G1, 40 (39.2)
Table 2 Clinical and laboratory data according to rs1127354 inosine triphosphate pyrophosphatase genotypes (mean ± SD)
CriteriaCCCA + AAP value
Number, n (%)93 (91.2)9 (8.8)
Age (yr)32.3 ± 7.334.4 ± 7.7 0.457
Sex (male/female)82/118/1
BMI25.4 ± 2.826.8 ± 1.6 0.046
Baseline Hb (g/dL)14 ± 1.214.3 ± 1.03 0.441
plt (× 103/μL)233.2 ± 62.1292.2 ± 74.3 0.046
WBCs (× 103/μL)6.2 ± 1.56.8 ± 1.1 0.172
ALT > ULN, n (%)71 (76.3)7 (77.7)> 0.99
Creatinine level (mg/dL)0.9 ± 0.460.98 ± 0.22 0.349
Baseline HCV RNA (log IU/mL)5.46 ± 0.75.4 ± 0.8> 0.99
Table 3 Logistic regression analysis during the first 12 wk of combination therapy
VariableUnivariateMultivariate
OR (95%CI)P valueOR (95%CI)P value
Sex (female)0.49 (0.1-2.4)0.3864.7 (0.9-26.4)0.123
Age (≥ 40 yr)0.66 (0.24-1.8)0.4211.02 (0.9-1.1)0.462
BMI ( ≤ 24)2.03 (0.82-5.01)0.1241.2 (1-1.5)0.068
Baseline Hb (< 15)0.14 (0.04-0.49)0.0020.8 (0.5-1.2)0.610
Baseline plt (< 200)0.26 (0.1-0.65)0.0040.9 (0.9-1)0.073
ITPA genotype (CC)6.36 (1.24-32.41)0.0250.4 (0.04-4.08)0.671
RBV dose ≥ 80%0.08 (0.01-0.3)0.00090.87 (0.82-0.92)0.00002
Table 4 The average ribavirin dose during 2 different time-points among inosine triphosphate pyrophosphatase CC and non CC genotypes
During first 12 wk12-48 wk of treatment
TotalCCCA + AATotalCCCA + AA
No. of patients10293991829
RBV dose (mg/wk), mean ± SD947 ± 151.4936 ± 148.31059 ± 144.1943 ± 153.2930.5 ± 149.61059 ± 144.1
P value0.0350.029